A Study of Toripalimab as Consolidation Therapy After Postoperative Chemoradiotherapy in HNSCC
This study is a phase II, open label, single-arm and exploratory clinical trial. The purpose of this study is to observe the efficacy and safety of consolidation immunotherapy with Toripalimab following postoperative radiotherapy or chemoradiotherapy for patients with locally advanced head and neck squamous cell carcinomas (HNSCC).
Head and Neck Squamous Cell Carcinomas
DRUG: Consolidation Toripalimab
2-year Disease-Free Survival Rate, The 2-year DFS rate was defined as the rate of progression or death due to disease recurrence within 2 years., 2 years
2-year overall survival rate, Number of patients with evidenced death / number of total patients., 2 years|Media Disease-free Survival (mDFS), The time at which disease progression or death due to disease progression occurred in 50% of patients., Up to 5 years|Overall survival, Overall survival will be defined as the time from day 1 of study treatment until death from any cause., 5 years|Adverse events, Percentage of adverse events that are possibly, probably or definitely related to study treatment., 90 days after the first dose of study treatment
This study is a phase II, open label, single-arm and exploratory clinical trial. The purpose of this study is to observe the efficacy and safety of consolidation immunotherapy with Toripalimab following postoperative radiotherapy or chemoradiotherapy for patients with locally advanced head and neck squamous cell carcinomas (HNSCC).